Evidence map›Paper›PMID 35619221›Full record

Trial reportJournal of pineal research2022

Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial.

Esben S Lauritzen, Ulla Kampmann, Mette G B Pedersen, Lise-Lotte Christensen, Niels Jessen, Niels Møller, Julie Støy

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of pineal research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Essential Oils and Melatonin as Functional Ingredients in Dogs.Animals : an open access journal from MDPI · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Esben S LauritzenSteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4517-1674
Ulla KampmannSteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Mette G B PedersenSteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Lise-Lotte ChristensenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Niels JessenSteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Niels MøllerSteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Julie StøySteno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Steno Diabetes Centers · DKAarhus University Hospital · DK

Funding

Det Frie Forskningsråd DFF7016-00168Steno Diabetes Center AarhusThe AP Moller Foundation 18-L-0156The Riisfort Foundation
6 · The paper itself

Abstract

The use of the sleep-promoting hormone melatonin is rapidly increasing as an assumed safe sleep aid. During the last decade, accumulating observations suggest that melatonin affects glucose homeostasis, but the precise role remains to be defined. We investigated the metabolic effects of long-term melatonin treatment in patients with type 2 diabetes including determinations of insulin sensitivity and glucose-stimulated insulin secretion. We used a double-blinded, randomized, placebo-controlled, crossover design. Seventeen male participants with type 2 diabetes completed (1) 3 months of daily melatonin treatment (10 mg) 1 h before bedtime (M) and (2) 3 months of placebo treatment 1 h before bedtime (P). At the end of each treatment period, insulin secretion was assessed by an intravenous glucose tolerance test (0.3 g/kg) (IVGTT) and insulin sensitivity was assessed by a hyperinsulinemic-euglycemic clamp (insulin infusion rate 1.5 mU/kg/min) (primary endpoints). Insulin sensitivity decreased after melatonin (3.6 [2.9-4.4] vs. 4.1 [3.2-5.2] mg/(kg × min), p = .016). During the IVGTT, the second-phase insulin response was increased after melatonin (p = .03). In conclusion, melatonin treatment of male patients with type 2 diabetes for 3 months decreased insulin sensitivity by 12%. Clinical use of melatonin treatment in dosages of 10 mg should be reserved for conditions where the benefits will outweigh the potential negative impact on insulin sensitivity.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceMelatoninBlood GlucoseCross-Over StudiesDouble-Blind MethodGlucoseHumansInsulinMaleBlood GlucoseGlucoseInsulinMelatoninindirect calorimetryinsulin secretioninsulin sensitivityinsulin signaling and rs10830963melatoninsleep

Identifiers

PMID35619221
PMCPMC9540532
OpenAlexW4281732126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.